Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLK286 + Carboplatin + Paclitaxel in Advanced NSCLC
NCT00088556Phase 2Completed
- Sponsor
- Telik, Inc.
- Start
- Aug 2004
- Primary completion
- May 2009
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canfosfamide in non-small cell lung cancer (NSCLC), sponsored by Telik, Inc. Primary endpoint: Study Objectives (Efficacy and Safety). Started Aug 2004; status: completed.
02
Drugs
canfosfamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00088556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088556.